Laryngeal squamous cell carcinoma · line 1 · None
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | local_therapy |
| Linked regimen | None |
| ID | IND-LARYNGEAL-EARLY-GLOTTIC-1L-TLM |
|---|---|
| Type | Indication |
| Status | reviewed 2026-07-11 | pending_clinical_signoff |
| Diseases | DIS-LARYNGEAL |
| Sources | SRC-NCCN-HNSCC-2025 |
Notes
STUB pending Clinical Co-Lead sign-off (CHARTER §6.1). Early glottic (T1-T2N0) organ-preservation pathway — TLM track, alternative of ALGO-LARYNGEAL-1L step 4. Default track: IND-LARYNGEAL-EARLY-GLOTTIC-1L-RT. Full Ukrainian rationale/ do_not_do prose deferred to a follow-up localization pass.
Used By
Algorithms
ALGO-LARYNGEAL-1L- ALGO-LARYNGEAL-1L
Indication
IND-LARYNGEAL-EARLY-GLOTTIC-1L-RT- IND-LARYNGEAL-EARLY-GLOTTIC-1L-RT